Imprinting defects in osteosarcoma: DNA- and chromatin-modifying drugs hold promise for osteosarcoma therapy.

@article{Sarver2016ImprintingDI,
  title={Imprinting defects in osteosarcoma: DNA- and chromatin-modifying drugs hold promise for osteosarcoma therapy.},
  author={Anne E. Sarver and Subbaya Subramanian},
  journal={Epigenomics},
  year={2016},
  volume={8 7},
  pages={
          885-8
        }
}
  • Anne E. Sarver, Subbaya Subramanian
  • Published in Epigenomics 2016
  • Biology, Medicine
  • The overall survival rate of patients with metastatic osteosarcoma has not improved over past three decades. In more than 70% of patients, current standard-of-care therapies ultimately fail to prevent relapse and metastasis, indicating a critical need for novel drugs [1]. Osteosarcoma may be considered to be primarily a disease of development, with the majority of cases occurring in pediatric patients. Inherited factors play a greater role in pediatric tumorigenesis compared with cancers… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    1
    Twitter Mention

    Citations

    Publications citing this paper.

    DNA methylation of noncoding RNAs: new insights into osteogenesis and common bone diseases

    VIEW 1 EXCERPT
    CITES BACKGROUND

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 26 REFERENCES

    Epigenetic regulators: Polycomb-miRNA circuits in cancer.